Document Classification

Section Type: METHODS

Text: Patients with metastatic or locally recurrent CRC who had previously received 5-flurouracil (5-FU), oxaliplatin, and irinotecan were assigned to receive EZN-2208 monotherapy (9 mg/m (2) on days 1, 8, and 15 every 28 days for patients with KRAS-mutant tumors only [arm A]), and patients with KRAS wild-type tumors were randomized (2:1) to receive either EZN-2208 plus cetuximab (400 mg/m (2) loading dose on day 1 followed by 250 mg/m (2) weekly starting on day 8 [arm B]) or irinotecan 125 mg/m (2) on days 1 and 8 every 21 days plus cetuximab at the same doses indicated above (arm C).